

Practitioner's Docket No. MPI03-043P1RNMRECEIVED  
CENTRAL FAX CENTER

JAN 29 2007

ELECTION OF INVENTION/SPECIES

Applicants elect **Group I**, without traverse, which includes claims 1-18, 28 and 29 (20 is written in the Restriction Requirement, but Applicants assume this is a typo and claim 29 was intended), drawn to the products of formula (I) classified in various subclasses of 514, 544, and 546. As required, Applicants also elect compound 40 (Example 40), 4-((S)-2-Acetylamino-propyl)-6,6-dimethyl-morpholine-3-(S)-carboxylic acid (6-chloro-9H- $\beta$ -carbolin-8-yl)-amide, as the single disclosed species for prosecution on the merits. Applicants reserve the right to pursue non-elected subject matter in subsequent continuing and divisional applications. Additionally, Applicants respectfully request that once product claims are found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claims will be considered for rejoinder.

REMARKS

Claims 1-34 are now pending in the above-referenced application. Applicants would like to thank the Examiner in advance for careful review of this application. If the Examiner believes that a telephone call would expedite prosecution of the above-referenced application, the Examiner is invited to call the undersigned at (617) 444-3227.

Applicants respectfully request an extension of time from December 27, 2006 up to and including January 29, 2007 (the next business day after January 27, 2007). In the event any additional fees are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Dated: January 29, 2007

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Karoline K. M. Shair  
Registration No. 44,332  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-444-3227  
Facsimile - 617-551-8820

(Page 22 of 22)